The Global Burden of Multidrug-Resistant Tuberculosis: An In-Depth Review of Catastrophic Costs, Patient Burdens, and Strategies for Sustainable Healthcare Solutions
Kayan Alotaibi, Afet Mater Zaid Alotibi, Muteb Qayyed Alotaibi, FARAH OJAYR SIRAJ ALOTAIBI, Mohammed Alotaibi, MUNIF RIDHA SHUKR ALOTAIBI, Ali Mutlaq Eid Alotaibi, Ghadeer Abdullah Alotaibi, et al. (10 authors)
Journal of Ecohumanism · 2024-12
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) poses a significant global health challenge, with approximately 500,000 new cases reported in 2020, predominantly among vulnerable populations in low- and middle-income countries. The World Health Organization (WHO) aims to mitigate catastrophic costs associated with TB treatment, which often exceed 20% of a household's annual income, leading families into severe financial distress. This systematic review and meta-analysis aimed to assess the global burden of catastrophic expenditures related to MDR-TB, focusing on patient and family financial impacts. Methods: A comprehensive literature search was conducted across five databases (CINAHL, MEDLINE, Embase, Scopus, and Web of Science) and grey literature sources, utilizing relevant keywords related to MDR-TB and cost implications. Studies were selected based on their relevance to catastrophic costs incurred by MDR-TB patients. Results: The analysis revealed that the financial burden for MDR-TB patients is significantly higher than for drug-susceptible TB (DS-TB) cases, with treatment costs ranging from $2,423 in Peru to $14,657 in Tomsk, Russia. Factors influencing these costs include sociodemographic characteristics, diagnostic delays, and the duration of hospitalization. Notably, 43% of TB patients experienced catastrophic expenditures, with MDR-TB patients facing an even greater risk due to longer treatment durations and higher medication costs. Conclusions: In conclusion, the findings underscore the urgent need for effective interventions to reduce the financial burden of MDR-TB on patients and families. Enhanced drug susceptibility testing and improved healthcare access are critical for managing MDR-TB and preventing further economic devastation. Addressing these issues will be vital for achieving the WHO's end-TB strategy and ensuring sustainable healthcare solutions
MeSH terms
- Tuberculosis
- Health care
- Medicine
- Intensive care medicine
- Multiple drug resistance
- Healthcare system